Systemic lupus erythematosus (CNS manifestations)
WEBMay 7, 2024 · Last revised by Joshua Yap on 7 May 2024. Edit article. Citation, DOI, disclosures and article data. Central nervous system manifestations of systemic lupus erythematosus (CNS lupus), also known as neuropsychiatric systemic lupus erythematosus (NPSLE), describe a very diverse range of neuropsychiatric …
「 自己免疫疾患全身性エリテマトーデス(SLE)の発症抑制の ...
WEBMay 22, 2024 · 慢性の疾患で継続的な治療が必要であり、主にステロイド剤や免疫抑制剤による治療が行われていますが、これらの治療法は免疫の全般的な抑制や代謝の異常などの種々の副作用をきたすため、疾患の病態に則した副作用のない治療法の開発が待ち望まれています。 SLEでは核酸や核酸を含む自己抗原に対する自己抗体が産生され、この …
Lupus - Wikipedia
WEBMay 26, 2024 · Lupus, technically known as systemic lupus erythematosus ( SLE ), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [1] Common symptoms include painful and swollen joints, fever, chest pain, hair loss, …
Disease-modifying therapies in systemic lupus erythematosus ...
WEBMay 22, 2024 · Introduction SLE is a chronic and heterogeneous autoimmune disease in which 30–50% of patients develop organ damage within 5 years of diagnosis. 1 Despite the available treatments for SLE, a systematic literature review of studies published after 2015 reported remission prevalence ranging from 21% to 70% at 5 years, and only 10% of …
Efficacy and safety study of targeted small-molecule drugs in ...
WEBMay 10, 2024 · Background Targeted small-molecule drugs in the treatment of systemic lupus erythematosus (SLE) have attracted increasing attention from clinical investigators. However, there is still a lack of evidence on the difference in the efficacy and safety of different targeted small-molecule drugs. Therefore, this study was conducted to assess …
Hypertension and Cardiovascular Outcomes in Inflammatory ...
WEB3 days ago · Purpose This review aimed to investigate the prevalence of hypertension and cardiovascular (CV) complications in various inflammatory and autoimmune diseases (IAD). Recent Findings Despite recent improvements in the management of IAD, patients with IAD still have an increased CV mortality and CV complications, mostly related to CV risk …
全身性エリテマトーデス（SLE）患者への支援内容とは：訪問 ...
WEBMay 8, 2024 · 全身性エリテマトーデス（SLE）は、自己免疫反応によって多臓器が同時に障害される原因不明の疾患です。 SLEは、厚生労働省が指定する特定疾患（指定難病）であり、訪問看護においても関わることのある病気の一つです。 今回は、全身性エリテマトーデス（SLE）をテーマにその概要から療養生活における支援内容やアセスメント項 …
Pediatric Systemic Lupus Erythematosus Differential ...
WEB6 days ago · Specific conditions to consider in the differential diagnosis of systemic lupus erythematosus (SLE) include the following: Acute anemia. Acute poststreptococcal glomerulonephritis. Chronic...
Uncoupling interferons and the interferon signature explains ...
WEBMay 13, 2024 · Systemic lupus erythematosus (SLE) displays a hallmark interferon (IFN) signature. Yet, clinical trials targeting type I IFN (IFN-I) have shown variable efficacy, and blocking IFN-II failed to treat SLE. Here, we show that IFN type levels in SLE vary significantly across clinical and transcriptional endotypes.
Pediatric Systemic Lupus Erythematosus Guidelines - Medscape
WEB6 days ago · Medication. Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in damage to essentially any organ. The disease can affect, for example, the kidneys, skin, blood cells, and nervous system.
- Some results have been removed
Skip to content